GURU.Markets stock price, segment price, and overall market index valuation
The company's share price SCYNEXIS Inc.
SCYNEXIS is a biopharmaceutical company specializing in the treatment of fungal infections. Its stock price is the story of the development and commercialization of its lead drug. The chart reflects both its success in obtaining approvals and the challenges of competing in the pharmaceutical market.
Share prices of companies in the market segment - Pharma infections
SCYNEXIS is a pharmaceutical company specializing in the development of antifungal drugs for the treatment of invasive and resistant infections. We've categorized it as "Pharma: Infections." The chart below shows how investors value companies tackling the growing problem of resistance.
Broad Market Index - GURU.Markets
SCYNEXIS is a pharmaceutical company specializing in the development of antifungal drugs for the treatment of invasive and resistant infections. As a component of the GURU.Markets index, it is tackling the growing problem of drug resistance. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
SCYX - Daily change in the company's share price SCYNEXIS Inc.
For SCYNEXIS, Inc., a developer of antifungal drugs, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and FDA decisions, and is key to assessing biotech risks.
Daily change in the price of a set of shares in a market segment - Pharma infections
SCYNEXIS, Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with SCYX, which focuses on treating fungal infections, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
SCYNEXIS is a pharmaceutical company specializing in the treatment of fungal infections. Its shares are driven by news about sales and the development of new drugs. This dynamic, specific to the pharmaceutical industry, creates fluctuations that contribute to the overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization SCYNEXIS Inc.
For SCYNEXIS, Inc., year-over-year performance is the story of its unique antifungal drug. Its market capitalization growth over the past 12 months reflects the successful approval and launch of its drug, Brexafemme, as well as its strategy to develop this asset for the treatment of more serious invasive fungal infections, which is its main bet for the future.
Annual dynamics of market capitalization of the market segment - Pharma infections
SCYNEXIS, Inc. is a pharmaceutical company focused on the development and commercialization of antifungal drugs. Its success depends on its key product for the treatment of invasive infections. The chart shows how its niche strategy and competitive environment influence its volatile performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
SCYNEXIS is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization SCYNEXIS Inc.
SCYNEXIS is a biopharmaceutical company focused on antifungal drugs. Its monthly performance reflects the commercial success of its approved drug Brexafemme and progress in expanding its indications. Quarterly sales reports are a key driver.
Monthly dynamics of market capitalization of the market segment - Pharma infections
SCYNEXIS develops drugs to combat fungal infections, which are becoming an increasingly serious threat. This pharmaceutical segment requires constant innovation due to the growing resistance of pathogens. The chart below shows how investors assessed the prospects of companies working on the next generation of antifungal agents.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
SCYNEXIS is a pharmaceutical company specializing in antifungal drugs. With an already approved product, its stock performance is driven by sales volume and successful market launches. This is a focused commercial strategy, less dependent on the risks of clinical trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization SCYNEXIS Inc.
SCYNEXIS is a biopharmaceutical company focused on fighting fungal infections. Its weekly stock price is volatile and depends on sales data for its approved drug, as well as the results of clinical trials to expand its indications. It's a classic example of a single-product biotech.
Weekly dynamics of market capitalization of the market segment - Pharma infections
SCYNEXIS is a biopharmaceutical company focused on fighting fungal infections. Its weekly stock price is volatile and depends on sales data for its approved drug, as well as the results of clinical trials to expand its indications. It's a classic example of a single-product biotech.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of SCYNEXIS, a biotech company, live in a world of their own. Their performance is determined by news about the sales of their drug. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can move independently of the broader market, reacting only to internal events.
Market capitalization of the company, segment and market as a whole
SCYX - Market capitalization of the company SCYNEXIS Inc.
SCYNEXIS's market capitalization tells the story of the development of a new class of antifungal drugs. Its graph reflects both the approval of the first drug and the subsequent commercial difficulties that led to the sale of the asset. It illustrates how scientific success doesn't always guarantee commercial success, and how the market revalues a company after such events.
SCYX - Share of the company's market capitalization SCYNEXIS Inc. within the market segment - Pharma infections
SCYNEXIS is a pharmaceutical company focused on developing new drugs for the treatment of fungal infections. Its share of its segment's market capitalization reflects the potential of its lead drug, BREXAFEMME. The chart below shows how its share depends on commercial success and indication expansion.
Market capitalization of the market segment - Pharma infections
SCYNEXIS is a pharmaceutical company focused on combating fungal infections, including those resistant to existing drugs. The chart below shows the overall market capitalization of the infectious pharmaceuticals sector. It reflects the growing threat of antimicrobial resistance and the importance of developing new classes of drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph represents the fight against fungal infections. SCYNEXIS is developing a new class of antifungal drugs to treat serious and resistant infections. Its volatile pipeline reflects both scientific success and the commercial challenges of bringing a new antibiotic to a challenging market.
Book value capitalization of the company, segment and market as a whole
SCYX - Book value capitalization of the company SCYNEXIS Inc.
SCYNEXIS's book value is derived from its intellectual property for a new class of antifungal drug and its financial reserves. This represents unique scientific capital for combating drug-resistant infections. The chart below shows how the company manages its resources after the approval and commercialization of its breakthrough drug.
SCYX - Share of the company's book capitalization SCYNEXIS Inc. within the market segment - Pharma infections
SCYNEXIS is a pharmaceutical company focused on fighting fungal infections. Its main assets are its approved drug and scientific research. The chart shows a modest share of physical assets, as its value lies in its intellectual property, not its own manufacturing facilities.
Market segment balance sheet capitalization - Pharma infections
Antifungal drug development, as the BCap_Seg chart for biotech shows, is a science-intensive endeavor. SCYNEXIS operates in this environment. Its capital is invested in clinical trials and commercialization of its unique drug, not in building gigantic factories.
Book value of all companies included in the broad market index - GURU.Markets
SCYNEXIS's assets are the capital and intellectual property associated with its antifungal drug. The book value reflects the financial foundation that supports the production and distribution of this highly tangible and medically important drug.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - SCYNEXIS Inc.
SCYNEXIS develops drugs to combat fungal infections. This is an important, yet niche, area of pharmaceuticals. The company's market capitalization is the valuation of its lead drug. The MvsBCap chart will reflect its commercial success and the company's ability to expand its use, which is key to its long-term value.
Market to book capitalization ratio in a market segment - Pharma infections
SCYNEXIS is a pharmaceutical company specializing in the treatment of fungal infections. Its value is determined by its drugs and scientific platform. The chart shows how the market perceives its potential to treat complex and drug-resistant infections.
Market to book capitalization ratio for the market as a whole
SCYNEXIS is developing a new class of antifungal drugs to combat resistant infections. Its value lies in this scientific innovation. Its market valuation reflects the potential of its drug to become a key tool in doctors' arsenal. The chart shows how investors value the science solving a pressing medical problem.
Debts of the company, segment and market as a whole
SCYX - Company debts SCYNEXIS Inc.
SCYNEXIS, a biopharmaceutical company focused on fighting fungal infections, is using capital to bring its drug to market and conduct further research. Commercialization requires significant investments in marketing and distribution. This chart shows how the company is funding its mission to develop new treatments against the growing threat of drug-resistant fungi.
Market segment debts - Pharma infections
SCYNEXIS is a pharmaceutical company specializing in the development of drugs to treat fungal infections. Combating drug-resistant pathogens requires constant innovation and investment in R&D. This chart shows how the company funds its research and how its financial structure compares to other players in this important niche.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio SCYNEXIS Inc.
SCYNEXIS develops drugs to combat fungal infections, which require lengthy and expensive clinical trials. This graph reflects its financial dependence on external capital. For a biopharmaceutical company, high debt is a bet on the success of its developments, and any research setback could jeopardize its future.
Market segment debt to market segment book capitalization - Pharma infections
SCYNEXIS is a pharmaceutical company specializing in the development of drugs to treat fungal infections. The chart reflects the debt burden in the sector. It helps understand how the company finances its research and commercialization in this important but often overlooked area of medicine, compared to other anti-infective drug manufacturers.
Debt to book value of all companies in the market
SCYNEXIS is a biotech company combating fungal infections with its innovative drugs. The overall level of debt in the economy, shown in this chart, affects the availability of funding for R&D. For companies bringing new antibiotics to market, a stable investment climate is key to successful development.
P/E of the company, segment and market as a whole
P/E - SCYNEXIS Inc.
The chart for SCYNEXIS, Inc., a company that fights fungal infections, shows how investors value its antifungal drug. The price action reflects the market's belief that the drug will become an important tool in the fight against resistant infections, ensuring stable demand in hospitals worldwide.
P/E of the market segment - Pharma infections
This chart shows the average P/E valuation for the pharmaceutical industry, where SCYNEXIS fights infections. This metric serves as a benchmark for assessing the premium the market is willing to pay for the company's antifungal drug, which addresses the problem of growing drug resistance.
P/E of the market as a whole
SCYNEXIS is a pharmaceutical company specializing in the development of new antifungal drugs for the treatment of invasive and drug-resistant infections. This chart shows the biotech sentiment. It helps understand how the market perceives the need for new antimicrobial agents and the commercial potential of SCYNEXIS's drugs in combating the growing threat of drug resistance.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company SCYNEXIS Inc.
SCYNEXIS is a pharmaceutical company specializing in the development of drugs to treat fungal infections. Its primary product targets drug-resistant strains. This chart shows analyst expectations for the commercial success of its antifungal drug in a market where there is a pressing need for new treatments.
%20P%2FE%20SCYNEXIS%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-SCYNEXIS-Inc.&v=1772553370007 "Chart of the company's future (projected) P/E SCYNEXIS Inc.")
Future (projected) P/E of the market segment - Pharma infections
SCYNEXIS is a pharmaceutical company specializing in the development of treatments for potentially life-threatening fungal infections. This chart shows analyst estimates for its future revenue, reflecting the urgent medical need for new antifungal agents and the potential of its lead drug.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-infections&v=1772553370146 "Future (projected) P/E graph of the market segment - Pharma infections")
Future (projected) P/E of the market as a whole
SCYNEXIS is a pharmaceutical company specializing in the treatment of fungal infections. Demand for its drugs is driven by medical needs, but its valuation as a public company is dependent on market sentiment. This chart, showing overall risk appetite, influences how investors value biotech companies, especially those in the commercialization stage.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772553370246 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit SCYNEXIS Inc.
SCYNEXIS, Inc. is a pharmaceutical company specializing in the development of antifungal drugs for the treatment of invasive infections. Its profitability depends on the market success of its key drug. This chart shows the company's progress from clinical development to commercialization, a critical milestone for any biotech company.
Profit of companies in the market segment - Pharma infections
SCYNEXIS is a pharmaceutical company focused on developing drugs to treat fungal infections. Its drug, BREXAFEMME®, is the first in a new class of antifungal agents. This chart shows the overall profitability of the infectious diseases sector, where the development of new, more effective drugs to combat resistant pathogens is highly sought after.
Overall market profit
SCYNEXIS develops drugs to treat fungal infections. Demand for anti-infectives is less elastic than for many other medications. However, the overall economic situation, reflected in the graph, still impacts the healthcare system and the availability of new, more expensive drugs for patients.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company SCYNEXIS Inc.
SCYNEXIS is a pharmaceutical company specializing in the treatment of fungal infections, including those resistant to existing drugs. This is a significant and growing problem in medicine. This chart reflects analyst expectations regarding the commercial success of its antifungal drugs and future revenue growth.
%20profit%20of%20the%20company%20SCYNEXIS%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-SCYNEXIS-Inc.&v=1772553370492 "Graph of future (projected) profit of the company SCYNEXIS Inc.")
Future (predicted) profit of companies in the market segment - Pharma infections
SCYNEXIS is a pharmaceutical company specializing in the development of new antifungal drugs for the treatment of invasive and drug-resistant infections. Its lead drug represents a new class of antifungal agents. This chart shows profitability forecasts for the pharmaceutical sector, providing context for assessing the importance of combating drug resistance.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-infections&v=1772553370629 "Graph of future (predicted) profits of companies in a market segment - Pharma infections")
Future (predicted) profit of the market as a whole
SCYNEXIS is a pharmaceutical company developing drugs to combat fungal infections. Despite medical necessity, budgets for new drugs may depend on the overall state of the healthcare system. The corporate profit forecast, shown in the graph, indirectly impacts the financial capabilities of hospitals and insurance companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772553370644 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - SCYNEXIS Inc.
SCYNEXIS is a biopharmaceutical company fighting fungal infections. This chart shows how the market evaluates the sales of its antifungal drugs. This ratio is a measure of the success of its commercialization and the acceptance of its drugs as an important treatment option.
P/S market segment - Pharma infections
SCYNEXIS, Inc. is a biotechnology company focused on developing innovative antifungal drugs. This chart reflects the average revenue estimate in the biotechnology sector. It provides an insight into how investors perceive the potential revenue from SCYNEXIS's drugs, which target serious and treatment-resistant fungal infections.
P/S of the market as a whole
SCYNEXIS is a pharmaceutical company focused on fighting fungal infections, which can be life-threatening, especially in hospitalized patients. Their drug represents a new class of antifungal agents. This chart provides a general measure of revenue valuation, which can be used to assess how investors value innovations in the fight against resistant infections.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company SCYNEXIS Inc.
SCYNEXIS is a pharmaceutical company that has developed a new class of antifungal drugs for the treatment of invasive fungal infections. This chart reflects market expectations for future sales of its innovative drug. This estimate depends on its acceptance by the medical community and its ability to address the growing problem of fungal resistance to existing drugs.
%20P%2FS%20SCYNEXIS%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-SCYNEXIS-Inc.&v=1772553370901 "The graph of the company's future (projected) P/S SCYNEXIS Inc.")
Future (projected) P/S of the market segment - Pharma infections
SCYNEXIS is a pharmaceutical company specializing in the development of new antifungal drugs for the treatment of invasive and drug-resistant infections. This chart shows how the market assesses the commercial potential of its lead drug compared to the infectious disease-focused pharmaceutical sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20infections&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-infections&v=1772553371013 "Future (projected) P/S market segment graph - Pharma infections")
Future (projected) P/S of the market as a whole
SCYNEXIS is a pharmaceutical company specializing in the development of drugs to treat fungal infections. This chart, reflecting the overall investment climate in the biotech sector, is important for the company. Market optimism facilitates raising the funding needed to bring new antifungal agents to market and conduct further research.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772553371076 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales SCYNEXIS Inc.
SCYNEXIS is a pharmaceutical company focused on fighting fungal infections. This chart shows revenue, comprised of sales of its first approved antifungal drug, as well as royalties from partners. The growth here reflects the commercial success of this new drug for the treatment of serious and difficult-to-treat infections.
Sales of companies in the market segment - Pharma infections
SCYNEXIS, Inc. is a biotechnology company focused on developing innovative treatments for life-threatening fungal infections. Its business is segmented by various drugs and formulations, particularly around its flagship product, BREXAFEMME®. This chart shows revenue from one of these key antifungal businesses.
Overall market sales
SCYNEXIS, Inc. is a pharmaceutical company specializing in the fight against fungal infections, particularly those resistant to existing drugs. Demand for its products is driven by medical need, not economic cycles. The company addresses a serious healthcare challenge, where the threat of pathogen resistance to antibiotics and antifungals is growing.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company SCYNEXIS Inc.
SCYNEXIS is a pharmaceutical company specializing in the development of antifungal drugs for the treatment of invasive and drug-resistant infections. Its sales forecast is based on the commercial success of its innovative antifungal agent, reflecting the growing need for new treatments for life-threatening fungal infections.
%20sales%20of%20the%20company%20SCYNEXIS%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-SCYNEXIS-Inc.&v=1772553371367 "Schedule of future (projected) sales of the company SCYNEXIS Inc.")
Future (projected) sales of companies in the market segment - Pharma infections
SCYNEXIS, Inc. is a pharmaceutical company developing new antifungal drugs for the treatment of invasive infections. This chart reflects expectations for the entire infectious diseases sector. It allows analysts to assess the demand for new antimicrobials predicted by analysts in the face of growing resistance.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-infections&v=1772553371472 "Schedule of future (projected) sales of companies in the market segment - Pharma infections")
Future (projected) sales of the market as a whole
SCYNEXIS, a pharmaceutical company, combats fungal infections. Demand for its drugs depends on physician acceptance and inclusion in insurance plans. This chart of overall sales forecasts reflects the state of the economy, which impacts healthcare budgets and the availability of innovative medications for patients.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772553371586 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality SCYNEXIS Inc.
SCYNEXIS, Inc. is a biotechnology company specializing in the development of innovative drugs for the treatment of fungal infections. This chart depicts its financial performance, where revenue from approved drug sales is balanced against research and commercialization expenses, creating a path to sustainable profitability.
Market segment marginality - Pharma infections
SCYNEXIS is a pharmaceutical company specializing in developing drugs to treat fungal infections. Focusing on this niche can provide a cost advantage, but it requires effective R&D. The graph shows how profitable their business model is compared to more diversified pharmaceutical companies.
Market marginality as a whole
SCYNEXIS, Inc. is a pharmaceutical company specializing in the development of new treatments for fungal infections. Fungal resistance to existing drugs makes this area critically important. This graph shows average profitability, but for SCYX, success depends on the ability to offer an effective solution to the growing problem of antimicrobial resistance.
Employees in the company, segment and market as a whole
Number of employees in the company SCYNEXIS Inc.
SCYNEXIS is a pharmaceutical company specializing in the treatment of fungal infections. Following approval of its drug, its team, as shown in this chart, had to expand. This growth reflects the creation of a commercial infrastructure to bring this life-saving drug to market.
Share of the company's employees SCYNEXIS Inc. within the market segment - Pharma infections
SCYNEXIS is a biopharmaceutical company focused on combating fungal infections, which pose a serious health threat. Developing new antifungal drugs is a complex task. This figure reflects the company's commitment to this important, yet often overlooked, area of medicine.
Number of employees in the market segment - Pharma infections
SCYNEXIS is a pharmaceutical company specializing in the treatment of fungal infections. This chart reflects employment in the infectious diseases sector. The growing number of researchers in this field highlights the global problem of antifungal resistance and the need for new classes of drugs like those developed by SCYNEXIS.
Number of employees in the market as a whole
SCYNEXIS is a pharmaceutical company that fights fungal infections. Demand for antifungal drugs is driven by medical needs, not the economy. This chart shows general trends, but for SCYNEXIS, the most important thing is regulatory approval of its drugs and their inclusion in treatment standards.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company SCYNEXIS Inc. (SCYX)
SCYNEXIS, Inc. is a pharmaceutical company specializing in the treatment of fungal infections. A high value on this chart indicates the company has an approved drug or promising developments. The market values the intellectual property and sales potential generated by a relatively small team.
%20of%20the%20company%20SCYNEXIS%20Inc.%20(SCYX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-SCYNEXIS-Inc.-SCYX&v=1772553372241 "Chart of market capitalization per employee (in thousands of dollars) of the company SCYNEXIS Inc. (SCYX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma infections
SCYNEXIS is a biotech company specializing in the development of drugs for the treatment of fungal infections. In this sector, market value per employee is an indicator of investor assessment of the scientific potential and commercial prospects of their lead drug. This allows them to compare the value of their developments with other pharmaceutical companies.
%20by%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-infections&v=1772553372289 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma infections")
Market capitalization per employee (in thousands of dollars) for the overall market
SCYNEXIS, Inc. is a pharmaceutical company focused on developing treatments for potentially life-threatening fungal infections. The chart illustrates how the market evaluates the scientific potential of the team working on developing new antifungal agents in the face of growing resistance.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772553372321 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company SCYNEXIS Inc. (SCYX)
SCYNEXIS, Inc. is a biopharmaceutical company that has developed a new class of antifungal drugs (their drug, Brexafemme, is approved). They combat resistant fungal infections. This chart shows how successfully the company is commercializing its breakthrough, yet niche, product. It measures how the sales and marketing team translates years of R&D into real profit per employee.
%20Chart%20SCYNEXIS%20Inc.%20(SCYX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-SCYNEXIS-Inc.-SCYX&v=1772553372332 "Company Profit Per Employee (in thousands of dollars) Chart SCYNEXIS Inc. (SCYX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma infections
SCYNEXIS is a biotech company fighting fungal infections with its drug BREXAFEMME. Following FDA approval, the team's key focus is on effective marketing and sales. This chart reflects their commercial success, showing how much revenue each employee generates compared to the pharmaceutical industry average.
%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-infections&v=1772553372339 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma infections")
Profit per employee (in thousands of dollars) for the market as a whole
SCYNEXIS (SCYX) is a pharmaceutical company specializing in the treatment of fungal infections, with the already approved drug BREXAFEMME. This metric helps assess commercial success. It shows how effectively the sales and marketing team promotes the drug and whether revenues cover R&D and administrative costs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772553372384 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee SCYNEXIS Inc. (SCYX)
SCYNEXIS is a pharmaceutical company specializing in the treatment of fungal infections. This chart shows the commercial trajectory of its flagship drug. The growth in revenue per employee demonstrates how successfully the company is promoting its product in the marketplace, competing with other antifungal agents.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-SCYNEXIS-Inc.-SCYX&v=1772553372428 "Sales chart per company employee SCYNEXIS Inc. (SCYX)")
Sales per employee in the market segment - Pharma infections
SCYNEXIS is a pharmaceutical company that developed the unique antifungal drug Brexafemme. It is their core asset. This chart compares SCYNEXIS's revenue per employee to the industry average. It demonstrates how effective their sales team (or partners) are in promoting and selling this single, yet important, drug.
Sales per employee for the market as a whole
SCYNEXIS (SCYX) is a biotech company that developed a new class of antifungal drugs (Brexafemme). They sold the rights to the drug, transitioning from a commercial model to a royalty-funded R&D model. This chart will reflect the revenue (royalties) generated by their small team focused on R&D.
Short shares by company, segment and market as a whole
Shares shorted by company SCYNEXIS Inc. (SCYX)
SCYNEXIS (SCYX) is a pharmaceutical company focused on developing a new class of antifungal drugs. Infectious diseases are a challenging market to commercialize. This chart shows the number of investors who doubt the company's drug (even if effective) will be competitive with existing low-cost generics.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-SCYNEXIS-Inc.-SCYX&v=1772553372519 "Short Shares Chart for the Company SCYNEXIS Inc. (SCYX)")
Shares shorted by market segment - Pharma infections
SCYNEXIS (SCYX) is a pharmaceutical company that has developed a new class of antifungal drugs (Ibrexafungerp) for the treatment of serious fungal infections. This chart shows the betting against the "anti-infective" biotech sector. It reflects investor doubts that a new (and expensive) antibiotic will be able to capture market share from existing generics.
Shares shorted by the overall market
SCYNEXIS (SCYX) is a clinical-stage biotech company. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like SCYX in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator SCYNEXIS Inc. (SCYX)
SCYNEXIS, Inc. is a pharmaceutical company that developed Brexafemme, a drug for the treatment of fungal infections. This chart tracks how investors view the drug's commercial launch, showing it as "overbought" (above 70) due to positive sales reports or "oversold" (below 30) due to competitive concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-SCYNEXIS-Inc.-SCYX&v=1772553372639 "RSI 14 indicator chart for the company's stock SCYNEXIS Inc. (SCYX)")
RSI 14 Market Segment - Pharma infections
SCYNEXIS (SCYX) is a pharmaceutical company specializing in the development of antifungal drugs for the treatment of invasive and drug-resistant infections. This chart measures the overall momentum of the pharmaceutical sector. It helps distinguish SCYX's movement related to its clinical data from the overall industry trend.
RSI 14 for the overall market
For SCYNEXIS, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SCYX (SCYNEXIS Inc.)
SCYNEXIS is the pharmaceutical company behind Brexafemme (ibrexafungerp), a first-in-class drug for the treatment of fungal infections. This chart shows the average target price. Analysts' forecasts are based on sales growth for this drug and its potential for treating more severe hospital-acquired infections.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SCYX-SCYNEXIS-Inc.&v=1772553372818 "A chart showing analyst consensus forecasts for the expected stock price. SCYX (SCYNEXIS Inc.)")
The difference between the consensus estimate and the actual stock price SCYX (SCYNEXIS Inc.)
SCYNEXIS is the biotech company that developed Brexafemme (Ibrexafungerp), a first-in-class drug for the treatment of fungal infections. This chart shows the difference between the current price and the analyst consensus estimate. It reflects their confidence in the drug's commercial success and its potential for treating invasive infections.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SCYX-SCYNEXIS-Inc.&v=1772553372972 "A chart showing the difference between the consensus forecast and the actual stock price. SCYX (SCYNEXIS Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma infections
SCYNEXIS is a biopharmaceutical company that developed Brexafemme, a first-in-class antifungal drug for the treatment of vaginal infections. This chart shows the overall expectations of analysts across the pharmaceutical sector. It reflects whether experts believe in the commercial success of new classes of antimicrobials.
Analysts' consensus forecast for the overall market share price
SCYNEXIS is a biopharmaceutical company specializing in the development of a new class of drugs (triterpenoids) for the treatment of fungal infections resistant to existing drugs. This chart shows the overall risk appetite. For SCYNEXIS, which operates in the "defensive" sector (infections need to be treated), overall optimism is important for funding R&D and bringing its innovative drugs to market.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index SCYNEXIS Inc.
SCYNEXIS is a fungus killer. They developed (and sold) Brexafemme, a first-of-its-kind oral (tablet) treatment for fungal infections. They are now focusing on R&D. This chart summarizes their transition. It reflects their future royalties from the drug sold and the market's confidence in their R&D platform for treating superfungi.
AKIMA Market Segment Index - Pharma infections
SCYNEXIS (SCYX) is a pharmaceutical company specializing in the treatment of fungal infections. Their flagship drug, Brexafemme, is a new class of antifungal agents for the treatment of serious infections. This chart shows the segment average. It helps investors assess how this important, yet niche, development compares to the sector average.
The AKIM Index for the overall market
SCYNEXIS is a biotech company that has developed a new class of antifungal drugs (Ibrexafungerp) for the treatment of severe fungal infections. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which has licensed the product to GSK, compares to overall economic trends.
